AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03750032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoloop
Description: The patients randomised for this intervention will undergo appendicular stump closure using Endoloop.
Study NCT03750032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hem-O-Lock
Description: The patients randomised for this intervention will undergo appendicular stump closure using Hem-O-Lock.
Study NCT02349334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Tibial Nerve Stimulation
Study NCT02349334 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous Tibial Nerve Stimulation
Study NCT02686606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vital 1.5
Description: Oral nutritional supplement
Study NCT02686606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ensure Plus
Description: Oral nutritional supplement
Study NCT03420131 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QFR and iFR
Description: iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option.~QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland
Study NCT06105424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung Permeability Assessment
Description: A gamma camera will be used to scintigraphically monitor the clearance of an inhaled radiolabeled tracer molecule from the lungs into the blood. Clearance will be monitored for 60 minutes. The rate of clearance of radioactivity will serve as an index of alveolar epithelial permeability.
Study NCT01912430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICC (Integrated Care Coaching) Intervention Group
Study NCT00739973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg tablet
Study NCT00739973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg capsule
Study NCT00739973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg capsule
Study NCT00739973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 150/5 mg tablet
Study NCT00739973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 150/10 mg tablet
Study NCT00739973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/5 mg tablet
Study NCT00739973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg tablet
Study NCT03932331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib 100 mg orally twice daily
Study NCT02220725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet
Study NCT02220725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02418455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UX003
Description: solution for intravenous infusion
Study NCT01397617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NobelActive Internal implant
Description: Dental implant
Study NCT01397617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NobelActive External implant
Description: Dental implant
Study NCT01397617 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NobelReplace Tapered Groovy implant
Description: Dental implant
Study NCT01467479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet
Study NCT01467479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study NCT01467479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection
Study NCT01467479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly Active Antiretroviral Therapy (HAART)
Description: Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
Study NCT02788799 — intervention group
Intervention type: OTHER
Intervention: Standard 12-Lead ECG
Description: Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.
Study NCT02788799 — intervention group
Intervention type: OTHER
Intervention: Posterior ECG Leads
Description: Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
Study NCT03186599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low adherence intervention group
Description: Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
Study NCT03389087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Etoposide Capsule
Description: Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
Study NCT01010750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate (LDX)
Description: Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
Study NCT01010750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Mixed Amphetamine Salts (MAS-IR)
Description: Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
Study NCT01010750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LDX Placebo + MAS-IR Placebo
Description: Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
Study NCT00108576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: anticonvulsant; mood stabilizer
Study NCT00108576 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Look-a-like placebo
Study NCT02510261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Patisiran was administered IV.
Study NCT01215071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: limited lymphadenectomy
Description: Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
Study NCT01215071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extended lymphadenectomy
Description: Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
Study NCT00777933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT00725985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif® new formulation (RNF)
Description: Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
Study NCT00725985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rebif® new formulation (RNF)
Description: Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.
Study NCT04109534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Bronchial allergen provocation (BAP)
Description: Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc... until the FEV1 decreases 20% below the initial FEV1-value
Study NCT04109534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial allergen provocation (BAP)
Description: Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc... until the FEV1 decreases 20% below the initial FEV1-value
Study NCT04109534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Nasal provocation test (NPT)
Description: Dermatophagoides farina will be administered in both nostrils
Study NCT04109534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal provocation test (NPT)
Description: Dermatophagoides farina will be administered in both nostrils
Study NCT04109534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Methacholine test
Description: Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
Study NCT04109534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Methacholine test
Description: Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
Study NCT04109534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Peak nasal expiratory flow (PNIF)
Description: Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
Study NCT04109534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Peak nasal expiratory flow (PNIF)
Description: Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
Study NCT03727854 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Premeal protein enriched bar
Description: Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
Study NCT03727854 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dietary modification
Description: Subjects in this group will follow diabetes diet education.
Study NCT03727854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary modification
Description: Subjects in this group will follow diabetes diet education.
Study NCT04392713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin 6 MG Oral Tablet (2 tablets)
Description: 12 mg single dose of Ivermectin will be given to intervention arm
Study NCT04286529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol capsules
Description: 0.25micrograms, taken daily for eight weeks, orally
Study NCT04286529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Placebo will be created to mimic the appearance of the study drug
Study NCT03408925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
Study NCT01086527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg tablet of montelukast (Singulair)
Description: Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
Study NCT02448381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGX301 (synthetic hypericin)
Description: 0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
Study NCT02448381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm\^2 fluorescent light.
Study NCT02150707 — intervention group
Intervention type: DRUG
Intervention: Dipeptidyl-Peptidase IV Inhibitors
Description: Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
Study NCT02150707 — intervention group
Intervention type: DRUG
Intervention: Glucagon-Like Peptide 1
Description: Glucagon-Like Peptide 1 to treat hyperglycaemia
Study NCT02040935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 600 mg SC Q3W by SID
Study NCT03999021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC effervescent tablets
Description: After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
Study NCT03748914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: After delivery of the neonate via caesarean section the umbilical cord will be clamped within 30 seconds and cut long at least 30 cm by the obstetrician. The neonate is then placed under an overhead heater by the midwife. There, the umbilical cord must be untwisted and held in a vertical position. It is milked once by the neonatologist towards the baby at a speed of approximately 10 cm/s and then clamped 3 cm from the umbilicus by one member of the clinical team.
Study NCT03748914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
Study NCT00777933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Study NCT02358733 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-cytoplasmic Sperm Injection
Description: Selection of sperm at 400x for sperm injection
Study NCT02358733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-cytoplasmic Morphologically-selected Sperm Injection
Description: Selection of sperm at 6000x for sperm injection
Study NCT01678651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation with human FSH
Description: Human FSH
Study NCT01678651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation with recombinant FSH
Description: Recombinant FSH
Study NCT01332786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~* Level 1: 50 mg daily x 10 doses; 1 week rest~* Level 2: 100 mg daily x 10 doses; 1 week rest~* Level 3: 150 mg daily x 10 doses; 1 week rest~* Level 4: 200 mg daily x 10 doses 1 week rest~* Level 5: 250 mg daily x 10 doses; 1 week rest~* Level 6: 300 mg daily x 10 doses; 1 week rest~* Level 7: 350 mg daily x 10 doses; 1 week rest
Study NCT03470584 — intervention group
Intervention type: OTHER
Intervention: Diet Exposure
Description: Vegetarian diet vs nonvegetarian diet
Study NCT03344484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical approach
Description: Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
Study NCT03359837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (HOE901)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study NCT00150748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 166 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 166 mg~* Route of Administration: Oral use
Study NCT00150748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 250 mg~* Route of Administration: Oral use
Study NCT00150748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Tablet~* Concentration: 500 mg~* Route of Administration: Oral use
Study NCT03359837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study NCT01103973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind/Body Program
Description: Ten week group mind/body program
Study NCT01103973 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Spa gift certificates
Study NCT03359837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic insulin aspart 30
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection
Study NCT03359837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study NCT03359837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study NCT03359837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet or capsule~Route of administration: oral administration
Study NCT00914836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Sodium Phosphate
Description: 1cc:2cc
Study NCT04126486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Zio®XT Monitor
Description: A Zio® XT monitor will be affixed to the participant's chest
Study NCT00914836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 cc - Betamethasone Sodium Phosphate
Description: Betamethasone Sodium Phosphate
Study NCT00914836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 cc - Betamethasone Sodium Phosphate
Description: Betamethasone Sodium Phosphate
Study NCT02417233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS text message
Description: bi-weekly behavioral messages and bi-weekly check-in messages
Study NCT02417233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS text message + Peer Navigation
Description: bi-weekly behavioral messages plus personalized peer navigation
Study NCT04184999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone intraocular suspension, 9%
Description: single dose intracameral corticosteroid
Study NCT04184999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% Oph Susp
Description: topical ophthalmic steroid drop
Study NCT04184999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Description: topical ophthalmic steroid drop
Study NCT01008384 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 50,000 units taken orally once a week for 8 weeks
Study NCT01745354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
Study NCT01745354 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Radiation
Study NCT03662256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current Primary Care Referral Process
Description: Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
Study NCT03662256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Referral Process
Description: In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.